구조모아 (StructureMoa)항암 chemical structure spider web
방문JohnsonJohnson
분석
큐레이션 브리핑
경쟁 포지션: IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression.
기전. Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IL-23 p19
Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease
US, EU, JP
Approved
tremfya · guselkumab · Tremfya · CNTO 1959
2026-09-10
Data Confidence · High
Development Signal · Established
Human IgG1λ monoclonal antibody
Binds the p19 subunit of IL-23 without affecting the shared p40 subunit of IL-12
Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low.
구조화 데이터
Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low.
Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond.
Human IgG1λ monoclonal antibody
IL-23 p19 · PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD.
Upper respiratory infection monitoring; no routine lab surveillance required
IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression.
Moderate-to-severe plaque psoriasis, active PsA, moderately-to-severely active UC and Crohn's disease
1L–2L biologic across dermatology, rheumatology, and gastroenterology
Subcutaneous, with IV induction in IBD
100 mg q8w after loading (psoriasis); IBD-specific induction and maintenance
Upper respiratory infection monitoring; no routine lab surveillance required
IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression.
Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa.
Immune-Mediated Inflammatory Diseases
PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD.
Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond.
구조화 데이터
Human, cynomolgus
~15–18 days
PASI 90/100, ACR20/50, endoscopic remission, serum IL-17A/IL-22
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (plaque psoriasis)
APPROVAL · 2017년 7월
Psoriatic arthritis indication
APPROVAL · 2020년 7월
Ulcerative colitis indication
APPROVAL · 2024년 9월
Crohn's disease indication
APPROVAL · 2025년 3월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
JohnsonJohnson
분석
큐레이션 브리핑
경쟁 포지션: IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression.
기전. Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IL-23 p19
Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease
US, EU, JP
Approved
tremfya · guselkumab · Tremfya · CNTO 1959
2026-09-10
Data Confidence · High
Development Signal · Established
Human IgG1λ monoclonal antibody
Binds the p19 subunit of IL-23 without affecting the shared p40 subunit of IL-12
Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low.
구조화 데이터
Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low.
Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond.
Human IgG1λ monoclonal antibody
IL-23 p19 · PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD.
Upper respiratory infection monitoring; no routine lab surveillance required
IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression.
Moderate-to-severe plaque psoriasis, active PsA, moderately-to-severely active UC and Crohn's disease
1L–2L biologic across dermatology, rheumatology, and gastroenterology
Subcutaneous, with IV induction in IBD
100 mg q8w after loading (psoriasis); IBD-specific induction and maintenance
Upper respiratory infection monitoring; no routine lab surveillance required
IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression.
Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa.
Immune-Mediated Inflammatory Diseases
PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD.
Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond.
구조화 데이터
Human, cynomolgus
~15–18 days
PASI 90/100, ACR20/50, endoscopic remission, serum IL-17A/IL-22
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (plaque psoriasis)
APPROVAL · 2017년 7월
Psoriatic arthritis indication
APPROVAL · 2020년 7월
Ulcerative colitis indication
APPROVAL · 2024년 9월
Crohn's disease indication
APPROVAL · 2025년 3월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.